Notch1 phenotype and clinical stage progression in non-small cell lung cancer

被引：0
|
作者：
Dat Nguyen
Larry Rubinstein
Naoko Takebe
Lucio Miele
Joseph E Tomaszewski
Percy Ivy
James H Doroshow
Sherry X Yang
机构：
[1] National Clinical Target Validation Laboratory,Stanley Scott Cancer Center
[2] Division of Cancer Treatment and Diagnosis,undefined
[3] National Cancer Institute,undefined
[4] National Institutes of Health,undefined
[5] Biometric Research Branch,undefined
[6] Division of Cancer Treatment and Diagnosis,undefined
[7] National Cancer Institute,undefined
[8] National Institutes of Health,undefined
[9] Cancer Therapy Evaluation Program,undefined
[10] Division of Cancer Treatment and Diagnosis,undefined
[11] National Cancer Institute,undefined
[12] National Institutes of Health,undefined
[13] Louisiana State University Health Sciences Center and Louisiana Cancer Research Consortium,undefined
[14] Division of Cancer Treatment and Diagnosis,undefined
[15] National Cancer Institute,undefined
[16] National Institutes of Health,undefined
来源：
Journal of Hematology & Oncology | / 8卷
关键词：
Lung cancer; N1-ICD; Notch1; NSCLC; Stage;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Circulating Angiogenesis Biomarkers are Predictive for Early Stage Non-Small Cell Lung Cancer Progression and Clinical Outcome
    Tarhoni, Imad
    Fhied, Cristina
    Pithadia, Ravi
    Seder, Christopher W.
    Basu, Sanjib
    Liptay, Michael
    Borgia, Jeffrey A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S259 - S260
  • [22] Stage III Non-small Cell Lung Cancer
    Rusch, Valerie W.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 37 (05) : 727 - 735
  • [23] Mediastinoscopy in patients with clinical stage I non-small cell lung cancer
    Choi, YS
    Shim, YM
    Kim, J
    Kim, K
    ANNALS OF THORACIC SURGERY, 2003, 75 (02): : 364 - 366
  • [24] Accuracy of Clinical Stage in Resectable Non-small Cell Lung Cancer (NSCLC)
    Gwon, H. R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S520 - S521
  • [25] Clinical staging underestimates pathological stage in non-small cell lung cancer
    Camporota, L
    THORAX, 2005, 60 (07) : 581 - 581
  • [26] The prognosis of clinical stage IIIa non-small cell lung cancer in Taiwan
    Cheng, Ya-Fu
    Huang, Jing-Yang
    Lin, Ching-Hsiung
    Wang, Bing-Yen
    CANCER MEDICINE, 2023, 12 (16): : 17087 - 17097
  • [27] Prognostic factors in clinical stage I non-small cell lung cancer
    Suzuki, K
    Nagai, K
    Yoshida, J
    Moriyama, E
    Nishimura, M
    Takahashi, K
    Nishiwaki, Y
    ANNALS OF THORACIC SURGERY, 1999, 67 (04): : 927 - 932
  • [28] JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1
    Wang, Qun
    Wu, Jing
    Wei, Hua
    Huang, Hui
    Huang, Ying
    Fang, Hongyan
    Gong, Xiaojun
    Sun, Jun
    Wu, Yujuan
    Lei, Changjiang
    Yu, Jinming
    Hu, Desheng
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2021, 138
  • [29] Low expression of Notch1 and combined Notch1/HES1 are associated with adverse survival factor for limited stage small cell lung cancer
    Lee, J.
    Hong, S. A.
    Hwang, H. W.
    Hong, S-H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Operative results of clinical stage I non-small cell lung cancer
    Yoshino, I
    Yamaguchi, M
    Tagawa, T
    Fukuyama, S
    Kameyama, T
    Osoegawa, A
    Maehara, Y
    LUNG CANCER, 2003, 42 (02) : 221 - 225
12345